Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of IDN-6556 in Severe Renal Impairment
NCT02039817Phase 1Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Jan 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of emricasan in Nonalcoholic steatohepatitis (NASH) and Liver cirrhosis (LC) (2 arms), sponsored by Conatus Pharmaceuticals Inc. Primary endpoints: Area Under the Curve at 48 hours and Maximum Plasma Concentration at 48 hours. Started Jan 2014; status: completed.
02
Drugs
emricasan
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02039817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039817.